Anti-diabetic effect of blockade of the renin-angiotensin system

Diabetes, Obesity and Metabolism

Volumn 8, Issue 4, 2006, Pages 396-403

  Ando, Katsuyuki ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Insulin resistance; Oxidative stress

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DELAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IMIDAPRIL; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PLACEBO; PRAZOSIN; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONHUMAN; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33748463754     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00526.x     Document Type: Review

References (46)

1. Zanchetti A, Hansson L, Dahloef B et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149-1159.
2. Toumilehto J, Rastenyte D, Birkenhaeger WH et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
3. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guideline for the Management of Hypertension for General Practitioners. Hypertens Res 2001; 24: 613-634.
4. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Guideline Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
6. Liu L, Choudhury SR, Okayama A et al. Changes in body mass index and its relationships to other cardiovascular risk factors among Japanese population: Results from the 1980 and 1990 National Cardiovascular Surveys in Japan. J Epidemiol 1999; 9: 163-174.
7. Gress TW, Nieto FJ, Shadar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-912.
8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
9. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14(Suppl. 4): 39-47.
10. ALLHAT officiers and coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 88: 1967-1975.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
12. Niklason A, Hedner T, Niskanen L et al. Development of diabetes is retarded by ACE inhibition in hypertensive patients -a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004; 22: 645-652.
13. Wing LMH, Reid CM, Ryan P et al. A Comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
14. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
15. Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
16. Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1285-1290.
17. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
18. Mancia G, Brown M, Castaigne A et al. INSIGHT: Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.
19. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens 2002; 20: 1879-1886.
20. Grassi G, Seravalle G, Dell'Oro R et al. CROSS Study: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
21. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
22. Lithell H, Hansson L, Skoog L et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
23. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
24. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
25. Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 1994; 7: 655-660.
26. Richey JM, Ader M, Moore D et al. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277: E920-E926.
27. Ogihara T, Asano T, Ando K et al. Angiotensin II-induced resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879.
28. Iimura O, Shimamoto K, Matsuda K et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353-357.
29. Iyer SN, Katovich MJ. Effect of acute and chronic losartan treatment to glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 1996; 9: 662-668.
30. Higashiura K, Ura N, Takada T et al. The effect of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000; 13: 290-297.
31. Navarro-Cid J, Maeso R, Perez-Vizcaino F et al. Effects of losartan on blood pressure, metabolic alteration, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension 1995; 26: 1074-1078.
32. Chen S, Noguchi Y, Izumida T et al. A comparison of the hypotensive and hypoglycemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 1996; 14: 1325-1330.
33. Nawano M, Anai M, Funaki M et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing transcription via insulin receptor substance proteins and improving vascular resistance in Zucker fatty rat. J Clin Invest 1999; 48: 1248-1255.
34. Paolisso G, Tagliamonte MR, Gambardella A et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997; 11: 307-312.
35. Tikellis C, Wookey PJ, Candido R et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
36. Velloso LA, Folli F, Sun XJ et al. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93: 12490-12495.
37. Henriksen EJ, Jacob S, Kinnick TR et al. Selective angiotensin II receptor antagonism reduces insulin resistance obese Zucker rats. Hypertension 2001; 38: 884-890.
38. Togashi N, Ura N, Higashiura K et al. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
39. Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004; 13: 291-297.
40. Sharma AM, Janke J, Gorzelniak K et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2000; 40: 609-811.
41. Jandeleit-Dahm KAM, Tikellis C, Reid CM et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
42. Rudich A, Kozlovsky N, Potashnik R et al. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 1997; 272: E935-E940.
43. Rudich A, Tirosh A, Potashnik R et al. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998; 47: 1562-1569.
44. Tirosh A, Potashnik R, Bashan N et al. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes: A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 1999; 274: 10595-10602.
45. Ogihara T, Asano T, Katagiri H et al. Oxidative stress induces insulin resistance by activating the nuclear factor-κB pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004; 47: 794-805.
46. Xing G, Shimosawa T, Ogihara T et al. Angiotensin II-induced insulin resistance is enhanced in adrenomedullin-deficient mice. Endocrinology 2004; 145: 3647-3651.